Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions

Rhea-AI Summary

BioXcel Therapeutics (BTAI) is sponsoring a virtual roundtable on Dec. 8, 2025 at 10:00 a.m. EST focused on treating acute agitation linked to bipolar disorder and schizophrenia.

Hosted by journalist Anjalee Khemlani, the one-hour event features Drs. Leslie Citrome, Marc Milano, and Leon Ravin discussing the potential for safe, self‑administered at‑home treatments and shifting care outside emergency and inpatient settings. The release cites an estimated 57–77 million annual at‑home agitation episodes in the U.S. Pre-registration is available and a recording will be posted to the BioXcel Therapeutics website.

News Market Reaction

+2.14%

16 alerts

+2.14% News Effect

+6.0% Peak in 5 hr 43 min

+$967K Valuation Impact

$46M Market Cap

0.6x Rel. Volume

On the day this news was published, BTAI gained 2.14%, reflecting a moderate positive market reaction. Argus tracked a peak move of +6.0% during that session. Our momentum scanner triggered 16 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $967K to the company's valuation, bringing the market cap to $46M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Annual agitation episodes (U.S.): 57–77 million episodes

1 metrics

Annual agitation episodes (U.S.) 57–77 million episodes Estimated yearly at-home agitation episodes in bipolar and schizophrenia patients in the U.S.

Market Reality Check

Price: $1.59 Vol: Volume 486,519 is below 2...

normal vol

$1.59 Last Close

Volume Volume 486,519 is below 20-day average 629,033 (relative volume 0.77). normal

Technical Price 2.07 is trading below 200-day MA of 2.35 and far under 52-week high 9.256.

Peers on Argus

BTAI gained 2.82% while key peers were mixed: JUNS +5.36%, MAIA +12.33%, ATNM +2...

1 Down

BTAI gained 2.82% while key peers were mixed: JUNS +5.36%, MAIA +12.33%, ATNM +2.11%, PDSB +1%, and VTVT -5.15%, indicating stock-specific rather than broad sector momentum.

Common Catalyst Select biotech peers like JUNS also had company-specific news, suggesting idiosyncratic catalysts rather than a unified sector driver.

Historical Context

5 past events · Latest: Dec 03 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 03	Medical event promo	Neutral	+2.1%	Announcement of expert roundtable on at-home acute agitation treatment.
Nov 12	Earnings and pipeline	Negative	-15.3%	Q3 losses and tight liquidity alongside late-stage program update.
Oct 14	Clinical data update	Positive	+0.4%	Positive correlation data from SERENITY At‑Home supporting planned sNDA.
Oct 13	Milestone celebration	Positive	+2.8%	Nasdaq bell-ringing tied to completion of SERENITY At‑Home trial.
Sep 18	Listing compliance	Positive	+3.8%	Regaining compliance with Nasdaq MVLS listing requirements.

Pattern Detected

Recent BTAI news has generally led to aligned reactions: positive operational or regulatory updates often saw modest gains, while negative financials coincided with a notable decline.

Recent Company History

Over the last few months, BioXcel news centered on late‑stage agitation programs and listing compliance. Positive milestones included completion of the SERENITY At‑Home pivotal trial and supportive correlation data, with modest gains of 0.38–3.79%. A Q3 2025 earnings update highlighting losses and liquidity pressure saw a -15.35% move. The current Dec. 3 roundtable announcement, tied to at‑home agitation care, continues the theme of building awareness around the same clinical opportunity.

Market Pulse Summary

This announcement highlights BioXcel’s effort to spotlight acute agitation care in bipolar disorder ...

Analysis

This announcement highlights BioXcel’s effort to spotlight acute agitation care in bipolar disorder and schizophrenia through a Dec. 8 roundtable, emphasizing self‑administered at‑home treatments amid an estimated 57–77 million U.S. episodes annually. Recent history shows progress in the SERENITY At‑Home program and continued Nasdaq compliance, alongside financial strain noted in Q3 filings. Investors may watch for future regulatory milestones and additional clinical data that could more directly affect the company’s outlook.

Key Terms

acute agitation, bipolar disorder, schizophrenia

3 terms

acute agitation medical

"struggle with acute agitation episodes associated with bipolar disorder and schizophrenia"

Acute agitation is a sudden, intense episode of restlessness, anxiety or aggressive behavior that can include pacing, shouting, threats or physical resistance and usually needs quick medical or security attention. For investors, it matters because reports of acute agitation in clinical trials or post-market safety data can influence regulators, product labels, prescribing habits and public perception—much like a sudden safety recall can change a product’s commercial outlook.

bipolar disorder medical

"acute agitation episodes associated with bipolar disorder and schizophrenia"

A mental health condition marked by repeated swings between very low mood and energy (depressive episodes) and unusually high mood or activity (manic or hypomanic episodes), where these shifts are more extreme than normal ups and downs. Investors care because it affects healthcare demand, workplace productivity, insurance costs, and the market value of companies that develop treatments or provide care—think of it like sudden stormy weather that can change forecasts for costs and revenues.

schizophrenia medical

"acute agitation episodes associated with bipolar disorder and schizophrenia"

A chronic brain disorder that changes how a person thinks, perceives reality, feels and interacts with others, often causing hallucinations, false beliefs and trouble organizing thoughts or daily life. It matters to investors because the condition creates demand for long‑term treatments, diagnostics and support services; developing effective therapies can be costly, risky and highly regulated, but successful drugs or devices can open large, steady markets—think of it like fixing a deep, complex software bug that many users rely on.

AI-generated analysis. Not financial advice.

Event Sponsored by BioXcel Therapeutics Set for 10 a.m. EST on Monday, Dec. 8

Topics Covered by Drs. Leslie Citrome, Marc Milano, and Leon Ravin to Include Opportunities and Advantages of Self-Administered Treatments at Home

NEW HAVEN, Conn., Dec. 03, 2025 (GLOBE NEWSWIRE) -- As millions of patients and caregivers continue to struggle with acute agitation episodes associated with bipolar disorder and schizophrenia, a timely and highly anticipated virtual roundtable will bring together leading medical experts to discuss the future of care, including the growing potential for safe, effective self-administered treatments at home.

Hosted by Anjalee Khemlani, an award-winning healthcare journalist known for her in-depth reporting at Yahoo Finance and NJBIZ, the one-hour event will take place Monday, Dec. 8, at 10 a.m. EST. Pre-registration is now open at the following link: https://event.webcasts.com/starthere.jsp?ei=1744467&tp_key=14d071615e.

With an estimated 57 to 77 million episodes of agitation associated with bipolar disorders and schizophrenia in the at-home setting occurring annually in the U.S., this roundtable aims to give clinicians, caregivers, investors, and healthcare professionals an inside look at how treatment paradigms are shifting, and what innovations may soon redefine patient care outside emergency rooms, psychiatric facilities, and skilled nursing settings.

The roundtable participants are:

• Leslie Citrome, M.D., M.P.H., Clinical Professor of Psychiatry and Behavioral Sciences at New York Medical College
  

• Marc A. Milano, M.D., FACEP, Chair, Department of Emergency Medicine at Newark Beth Israel Medical Center and Children’s Hospital of New Jersey
  

• Leon Ravin, M.D., Psychiatrist and Statewide Psychiatric Medical Director for the Division of Public and Behavioral Health, State of Nevada
  

Attendees may ask questions via written Q&A. A recording of the event will be posted to the BioXcel Therapeutics website and available here.

About BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company built on artificial intelligence to develop transformative medicines in neuroscience. Its wholly owned subsidiary, OnkosXcel Therapeutics, is focused on the development of medicines in immuno-oncology. The Company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indications. For more information, please visit bioxceltherapeutics.com.

Contact Information:

Corporate/Investors
Russo Partners
Nic Johnson
nic.johnson@russopartnersllc.com
1.303.482.6405

Media
Russo Partners
David Schull
david.schull@russopartnersllc.com
1.858.717.2310

Source: BioXcel Therapeutics, Inc.

FAQ

When is the BioXcel Therapeutics (BTAI) virtual roundtable on acute agitation?

The event is scheduled for Monday, Dec. 8, 2025 at 10:00 a.m. EST.

Who is hosting the BioXcel (BTAI) virtual roundtable on Dec. 8, 2025?

The session is hosted by award‑winning journalist Anjalee Khemlani.

Which medical experts will speak at the BTAI roundtable on treating acute agitation?

Speakers are Leslie Citrome, M.D., Marc A. Milano, M.D., and Leon Ravin, M.D.

What topics will the BioXcel (BTAI) roundtable cover about at‑home agitation care?

The panel will discuss the opportunities and advantages of self‑administered treatments at home and changes in care pathways outside ERs and inpatient settings.

How many at‑home agitation episodes does the BTAI announcement reference?

The announcement cites an estimated 57 to 77 million at‑home agitation episodes annually in the U.S.

How can investors and clinicians access the BTAI roundtable or recording?

Pre‑registration is available via the event link and a recording will be posted to the BioXcel Therapeutics website after the event.